Vertex Pharma (VRTX) Offering Possible 19.05% Return Over the Next 10 Calendar Days

Vertex Pharma's most recent trend suggests a bearish bias. One trading opportunity on Vertex Pharma is a Bear Call Spread using a strike $157.50 short call and a strike $162.50 long call offers a potential 19.05% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $157.50 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $4.20 would be incurred if the stock rose above the $162.50 long call strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Vertex Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Vertex Pharma is bullish.

The RSI indicator is at 69.61 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Vertex Pharma

Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings
Sat, 05 Aug 2017 00:01:00 +0000
Vertex Pharmaceuticals and Regeneron Pharmaceuticals are enjoying rapid sales and profit growth this year. Did one of them execute on their strategy better than the other last quarter?

Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
Thu, 03 Aug 2017 23:45:00 +0000
The company reported mid-stage trial data that suggests it may be able to treat even more cystic fibrosis patients someday.

Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons
Thu, 03 Aug 2017 13:46:02 +0000
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has shined bright within the biotech industry this year. VRTX stock has more than doubled over the past 12 months. Then the company added more fuel to the fire last month, with new drug data results coming in favorably.

Corporate News Blog – Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis
Thu, 03 Aug 2017 11:10:00 +0000
Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 3, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for …

Vertex’s latest FDA nod could boost sales by $150M: analyst
Wed, 02 Aug 2017 16:35:08 +0000
Vertex Pharmaceuticals could see its annual revenue increase by more than $150 million following an FDA decision on Tuesday that will allow hundreds of new patients to use its cystic fibrosis drug Kalydeco, according to one analyst. The FDA initially approved Kalydeco in 2012 for cystic fibrosis patients with one specific type of genetic mutation that causes the lung disease, but it has since gradually expanded the approval to cover additional patients. The latest boost came on Tuesday, when Vertex (VRTX) said that the FDA had approved Kalydeco for use in more than 600 patients who have any of five different mutations.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.